Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8957079 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8697711 | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(3 years from now) | |
US9181257 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8735403 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US7514444 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(4 years from now) | |
US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8497277 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8754091 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8703780 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8476284 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8952015 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(4 years from now) | |
US8754091
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8957079
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8952015
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US7514444
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US9181257
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8703780
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8497277
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8697711
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8735403
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8476284
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
US8563563
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(4 years from now) | |
US8008309
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(5 years from now) | |
US10478439 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US8754090 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US9801883 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US10653696 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
US10751342 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US9125889 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US8999999 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US9801881 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
US10004746 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US10016435 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
US9814721 | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
US8754090
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US10004746
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US9814721
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
US8999999
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US9801881
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
US9125889
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US9801883
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US10653696
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
US10751342
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US10016435
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US10478439
(Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
US10961251
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US10294232
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US10294231
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US10125140
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US9725455
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US9713617
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US10106548
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US10752634
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
US9540382
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(10 years from now) | |
US9296753
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(11 years from now) | |
US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
US9795604
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
US10463668
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
US10695350
(Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(12 years from now) | |
US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
US9655857
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US10828259
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US10010507
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US10213386
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
ODE* (ODE*) | Aug 2, 2024 |
New Patient Population (NPP) | Aug 24, 2025 |
Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; Treatment of chronic lymphocytic leukemia; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of marginal zone lymphoma; Treatment of small lymphocytic lymphoma; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of waldenstrom's macroglobulinemia; Treatment of mantle cell lymphoma; Treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion; Treatment of relapsed or refractory small lymphocytic lymphoma; Treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of refractory chronic graft-versus-host disease
Dosage: TABLET;ORAL
167
United States
27
Japan
22
European Union
21
Canada
21
Australia
16
New Zealand
16
Korea, Republic of
13
China
12
Israel
10
Singapore
10
Hungary
9
Spain
9
Mexico
8
EA
8
South Africa
8
Slovenia
8
Poland
7
Portugal
7
Taiwan, Province of China
7
Lithuania
7
Cyprus
7
Denmark
6
Brazil
6
Philippines
5
Hong Kong
4
Argentina
4
Chile
3
Dominican Republic
3
Morocco
3
Luxembourg
2
Uruguay
2
Jordan
2
Peru
2
Ukraine
2
Ecuador
1
Malaysia
1
Russia
1
Guatemala
1
Costa Rica
1
Colombia
1
Austria
1
Tunisia
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic